Michael S Hofman1,2, Louise Emmett2,3, John Violet1,2, Alison Y Zhang2,4, Nicola J Lawrence2,4, Martin Stockler2,4, Roslyn J Francis5,6, Amir Iravani1, Scott Williams1,2, Arun Azad1,2, Andrew Martin2,4, Margaret McJannett2, Ian D Davis2,7,8. 1. Peter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. 2. Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, NSW, Australia. 3. St Vincent's Hospital, Sydney, NSW, Australia. 4. NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia. 5. Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia. 6. Australasian Radiopharmaceutical Trials Network (ARTnet). 7. Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia. 8. Eastern Health, Melbourne, VIC, Australia.
Abstract
OBJECTIVE: To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), in men with metastatic castration-resistant prostate cancer (mCRPC) who have received priordocetaxel treatment. PATIENTS AND METHODS: The TheraP trial (ANZUP 1603) is an open-label, randomized, stratified, two-arm multicentre phase 2 trial comparing the activity and safety of cabazitaxel chemotherapy vs 177 Lu-PSMA-617 therapy in the treatment of men with mCRPC. Key eligibility criteria include prior docetaxel chemotherapy, rising prostate-specific antigen (PSA) level, sufficient PSMA avidity, as defined by centrally reviewed 68 Ga-PSMA-11 and fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) with no discordant FDG-avid PSMA-negative sites of disease. Patients in the control group receive standard treatment with cabazitaxel (20 mg/m2 ) i.v. every 3 weeks with prednisolone 10 mg daily orally, for a maximum of 10 cycles. Patients in the experimental group receive 177 Lu-PSMA-617 (8.5 GBq decreasing by 0.5 GBq per cycle) i.v. every 6 weeks, for up to a maximum of six cycles. In the event of an exceptional response as defined on centrally reviewed post-therapy single-photon emission CT imaging, treatment will be suspended but can recommence on progression. The trial aims to include 200 patients who will be centrally randomized to one of the two treatment groups, in a 1:1 ratio. The primary endpoint is PSA response. Secondary endpoints are overall survival, progression-free survival (PFS), radiographic PFS, PSA PFS, objective tumour response, pain response, pain PFS, health-related quality of life, and frequency and severity of adverse events. The treatment and outcomes of patients excluded on the basis of low PSMA avidity or discordant FDG-avid disease on screening 68 Ga-PSMA-11 andFluorine-18 (18 F)-FDG-PET/CT scan will also be assessed. Enrolment in the study commenced on 29 January 2018. RESULTS AND CONCLUSIONS: 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC. The results of this trial will determine, for the first time in a randomized design, the activity and safety of 177 Lu-PSMA-617, as compared with cabazitaxel chemotherapy in men with progressive mCRPC.
RCT Entities:
OBJECTIVE: To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), in men with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel treatment. PATIENTS AND METHODS: The TheraP trial (ANZUP 1603) is an open-label, randomized, stratified, two-arm multicentre phase 2 trial comparing the activity and safety of cabazitaxel chemotherapy vs 177 Lu-PSMA-617 therapy in the treatment of men with mCRPC. Key eligibility criteria include prior docetaxel chemotherapy, rising prostate-specific antigen (PSA) level, sufficient PSMA avidity, as defined by centrally reviewed 68 Ga-PSMA-11 and fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) with no discordant FDG-avid PSMA-negative sites of disease. Patients in the control group receive standard treatment with cabazitaxel (20 mg/m2 ) i.v. every 3 weeks with prednisolone 10 mg daily orally, for a maximum of 10 cycles. Patients in the experimental group receive 177 Lu-PSMA-617 (8.5 GBq decreasing by 0.5 GBq per cycle) i.v. every 6 weeks, for up to a maximum of six cycles. In the event of an exceptional response as defined on centrally reviewed post-therapy single-photon emission CT imaging, treatment will be suspended but can recommence on progression. The trial aims to include 200 patients who will be centrally randomized to one of the two treatment groups, in a 1:1 ratio. The primary endpoint is PSA response. Secondary endpoints are overall survival, progression-free survival (PFS), radiographic PFS, PSA PFS, objective tumour response, pain response, pain PFS, health-related quality of life, and frequency and severity of adverse events. The treatment and outcomes of patients excluded on the basis of low PSMA avidity or discordant FDG-avid disease on screening 68 Ga-PSMA-11 and Fluorine-18 (18 F)-FDG-PET/CT scan will also be assessed. Enrolment in the study commenced on 29 January 2018. RESULTS AND CONCLUSIONS: 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC. The results of this trial will determine, for the first time in a randomized design, the activity and safety of 177 Lu-PSMA-617, as compared with cabazitaxel chemotherapy in men with progressive mCRPC.
Authors: Hallie M Hintz; Joseph P Gallant; Donald J Vander Griend; Ilsa M Coleman; Peter S Nelson; Aaron M LeBeau Journal: Clin Cancer Res Date: 2020-07-07 Impact factor: 12.531
Authors: Hojjat Ahmadzadehfar; Ralf Matern; Richard P Baum; Robert Seifert; Katharina Kessel; Martin Bögemann; Clemens Kratochwil; Hendrik Rathke; Harun Ilhan; Hanna Svirydenka; Mike Sathekge; Levent Kabasakal; Anna Yordanova; Francisco Osvaldo Garcia-Perez; Kalevi Kairemo; Masha Maharaj; Diana Paez; Irene Virgolini; Kambiz Rahbar Journal: Eur J Nucl Med Mol Imaging Date: 2021-05-25 Impact factor: 9.236
Authors: Panagiotis J Vlachostergios; Muhammad Junaid Niaz; Myrto Skafida; Seyed Ali Mosallaie; Charlene Thomas; Paul J Christos; Joseph R Osborne; Ana M Molina; David M Nanus; Neil Harrison Bander; Scott T Tagawa Journal: Prostate Date: 2021-01-19 Impact factor: 4.104
Authors: Francesco Ceci; Daniela E Oprea-Lager; Louise Emmett; Judit A Adam; Jamshed Bomanji; Johannes Czernin; Matthias Eiber; Uwe Haberkorn; Michael S Hofman; Thomas A Hope; Rakesh Kumar; Steven P Rowe; Sarah M Schwarzenboeck; Stefano Fanti; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2021-02-19 Impact factor: 9.236
Authors: Eline A M Ruigrok; Nicole van Vliet; Simone U Dalm; Erik de Blois; Dik C van Gent; Joost Haeck; Corrina de Ridder; Debra Stuurman; Mark W Konijnenberg; Wytske M van Weerden; Marion de Jong; Julie Nonnekens Journal: Eur J Nucl Med Mol Imaging Date: 2020-10-23 Impact factor: 9.236